4TZR

Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1561


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.207 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Vidadala, R.S.Rivas, K.L.Ojo, K.K.Hulverson, M.A.Zambriski, J.A.Bruzual, I.Schultz, T.L.Huang, W.Zhang, Z.Scheele, S.DeRocher, A.E.Choi, R.Barrett, L.K.Siddaramaiah, L.K.Hol, W.G.Fan, E.Merritt, E.A.Parsons, M.Freiberg, G.Marsh, K.Kempf, D.J.Carruthers, V.B.Isoherranen, N.Doggett, J.S.Van Voorhis, W.C.Maly, D.J.

(2016) J. Med. Chem. 59: 6531-6546

  • DOI: 10.1021/acs.jmedchem.6b00760
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-depend ...

    New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) that possesses antitoxoplasmosis activity in vitro and in vivo. Unfortunately, 1 has potent human ether-a-go-go-related gene (hERG) inhibitory activity, associated with long Q-T syndrome, and consequently presents a cardiotoxicity risk. Here, we describe the identification of an optimized TgCDPK1 inhibitor 32, which does not have a hERG liability and possesses a favorable pharmacokinetic profile in small and large animals. 32 is CNS-penetrant and highly effective in acute and latent mouse models of T. gondii infection, significantly reducing the amount of parasite in the brain, spleen, and peritoneal fluid and reducing brain cysts by >85%. These properties make 32 a promising lead for the development of a new antitoxoplasmosis therapy.


    Related Citations: 
    • Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.
      Ojo, K.K.,Larson, E.T.,Keyloun, K.R.,Castaneda, L.J.,Derocher, A.E.,Inampudi, K.K.,Kim, J.E.,Arakaki, T.L.,Murphy, R.C.,Zhang, L.,Napuli, A.J.,Maly, D.J.,Verlinde, C.L.,Buckner, F.S.,Parsons, M.,Hol, W.G.,Merritt, E.A.,Van Voorhis, W.C.
      (2010) Nat.Struct.Mol.Biol. 17: 602
    • Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
      Larson, E.T.,Ojo, K.K.,Murphy, R.C.,Johnson, S.M.,Zhang, Z.,Kim, J.E.,Leibly, D.J.,Fox, A.M.,Reid, M.C.,Dale, E.J.,Perera, B.G.,Kim, J.,Hewitt, S.N.,Hol, W.G.,Verlinde, C.L.,Fan, E.,Van Voorhis, W.C.,Maly, D.J.,Merritt, E.A.
      (2012) J.Med.Chem. 55: 2803


    Organizational Affiliation

    Department of Chemistry, University of Washington , Seattle, Washington 98195, United States.,Department of Microbiology and Immunology, University of Michigan Medical School , Ann Arbor, Michigan 48109, United States.,Paul G. Allen School for Global Animal Health, College of Veterinary Medicine, Washington State University , Pullman, Washington 99164, United States.,AbbVie , North Chicago, Illinois 60064, United States.,Department of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-Emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States.,Portland VA Medical Center , Portland, Oregon 97239, United States.,Center for Infectious Disease Research (formerly Seattle Biomedical Research Institute), Seattle, Washington 98109, United States.,Department of Pharmaceutics, University of Washington , Seattle, Washington 98195, United States.,Department of Biochemistry, University of Washington , Seattle, Washington 98195, United States.,Department of Global Health, University of Washington , Seattle, Washington 98195, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Calmodulin-domain protein kinase 1
A
484Toxoplasma gondiiMutation(s): 0 
Gene Names: CDPK1
Find proteins for Q9BJF5 (Toxoplasma gondii)
Go to UniProtKB:  Q9BJF5
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
UW2
Query on UW2

Download SDF File 
Download CCD File 
A
1-{4-amino-3-[2-(cyclopropyloxy)quinolin-6-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-2-methylpropan-2-ol
C21 H22 N6 O2
NJEBVFDXJAFAGB-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.207 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 48.240α = 90.00
b = 73.090β = 100.38
c = 66.240γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
Aimlessdata scaling
REFMACrefinement
REFMACrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2014-07-10 
  • Released Date: 2014-08-27 
  • Deposition Author(s): Merritt, E.A.

Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious DiseasesUnited StatesAI089441

Revision History 

  • Version 1.0: 2014-08-27
    Type: Initial release
  • Version 1.1: 2017-09-20
    Type: Author supporting evidence, Database references, Derived calculations, Other, Source and taxonomy, Structure summary
  • Version 1.2: 2017-11-08
    Type: Database references